Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation

Nephrology Dialysis Transplantation

Volumn 17, Issue 11, 2002, Pages 1931-1935

  Caglar, Kayser ^a   Kinalp, Can ^a   Arpaci, Fikret ^a   Turan, Mustafa ^a   Saglam, Kenan ^a   Ozturk, Bekir ^a   Komurcu, Şeref ^a   Yavuz, Izzet ^a   Yenicesu, Müjdat ^a   Ozet, Ahmet ^a   Vural, Abdülgaffar ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Antineoplastic agent toxicity; Autologous bone marrow transplantation; High dose chemotherapy; Nephrotoxicity

Indexed keywords

ALLOPURINOL; AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BICARBONATE; CALCIUM; CARBOPLATIN; CEFTAZIDIME; CISPLATIN; CREATININE; ETOPOSIDE; IFOSFAMIDE; IMIPENEM; MESNA; POTASSIUM; ALKYLATING AGENT; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BICARBONATE BLOOD LEVEL; BLOOD TOXICITY; BRAIN TUMOR; BREAST CANCER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; EWING SARCOMA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY FUNCTION; LUNG SMALL CELL CANCER; LYMPHOMA; MALE; MAXIMUM PERMISSIBLE DOSE; MORTALITY; NASOPHARYNX CARCINOMA; NEPHROTOXICITY; OSTEOSARCOMA; PERIPHERAL BLOOD STEM CELL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; TESTIS CANCER; ADOLESCENT; AUTOTRANSPLANTATION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; INFECTION; KIDNEY DISEASE; MIDDLE AGED; PROSPECTIVE STUDY; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; INFECTION; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036843102     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.11.1931     Document Type: Article

References (19)

1. Beyer J, Kingreen D, Krause M et al. Long term survival of patients with recurrent or refractory germ cell tumors after high-dose chemotherapy. Cancer 1997; 79: 161-168
2. Elias AD, Ayash LJ, Wheeler C et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow, Transplant 1995; 15: 373-379
3. Perkins JB, Fields KK, Elfenbein GJ et al. Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: Evaluation of dose-response relationships. Semin Oncol 1995; 22: 5-8
4. Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. J Clin Oncol 1994; 12: 1223-1231
5. Zager RA, O'Quigley J, Zager BK et al. Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis 1989: 210-216
6. Agoliotis DP, Ballester OF, Mattox T et al. Nephrotoxicity of high-dose ifosfamide, carboplatine, etoposide in adults undergoing stem cell transplantation. Am J Med Sci 1997; 314: 292-298
7. Lotz JP, Andree T, Donsimoni R et al. High-dose chemotherapy with ifosfamide, carboplatin and etoposide combined with autologous bone marrow transplantation for the treatment of poor prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 1995; 75: 874-885
8. Beyer J, Rick O, Weinknecht S, Kingreen D, Lenz K, Siegert W. Nephrotoxicity after high-dose carboplatin, etoposide, ifosfamide in germ cell tumors: Incidence and implications for hematologic recovery and clinical outcome. Bone Marrow Transplant 1997; 20: 813-819
9. Levey AS, Greene T, Kusek JW, Beck G.J. A simplified equation to predict glomerular filtration rate for serum creatinine. J Am Soc Nephrol 2000; 11: A0828 (Abstract)
10. Fields KK, Elfenbein GJ, Lazarus HM et al. Maximum tolerated doses of ifosfamide, carboplatin and etoposide given over 6 days followed by autologous stem-cell rescue: Toxicity profile. J Clin Oncol 1995; 13: 323-332
11. Margolin BK, Doroshow JH, Ahn C et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin and etoposide stem-cell support. J Clin Oncol 1996; 10: 2631-2637
12. Perkins JB, Elfenbein GJ, Fields KK. Analysis of dose-response relationships in the setting of ifosfamide, carboplatin and etoposide and autologous hematopoietic stem cell transplantation: Implications for the treatment of patients with advanced breast cancer. Semin Oncol 1996; 23: 42-46
13. McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med 1991; 90: 386-391
14. Zager RA. Acute renal failure in the setting of bone marrow transplantation. Kidney lnt 1994; 46: 1443-1458
15. Rossi R. Nephrotoxicity of ifosfamide - moving towards understanding the molecular mechanism. Nephrol Dial Transplant 1997; 12: 1091-1092
16. Goren MP, Wright RK, Horowitz ME, Meyer WH. Enhancement of methotrexate nephrotoxicity after cisplatin therapy. Cancer 1986; 58: 2617-2621
17. Rose BD, Black RM. Manual of Clinical Problems in Nephrology. Little Brown and Company, Boston, 1988; 139-144
18. Albright RC. Acute renal failure: A practical update. Mayo Clin Proc 2001; 76: 67-74
19. Rossi R, Godde A, Kleinebrand A et al. Unilateral nephrectomy and cisplatinum as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994; 12: 159-165